Summit Therapeutics, Inc. (SMMT)
14.16
+0.54
(+3.96%)
USD |
NASDAQ |
Sep 01, 16:00
14.16
0.00 (0.00%)
After-Hours: 17:23
Summit Therapeutics Total Long Term Debt (Quarterly) : 16.83M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 16.83M |
| March 31, 2026 | 16.86M |
| December 31, 2025 | 17.50M |
| September 30, 2025 | 2.708M |
| June 30, 2025 | 2.435M |
| March 31, 2025 | 2.907M |
| December 31, 2024 | 3.453M |
| September 30, 2024 | 28.71M |
| June 30, 2024 | 105.02M |
| March 31, 2024 | 105.82M |
| December 31, 2023 | 103.29M |
| September 30, 2023 | 103.88M |
| June 30, 2023 | 104.33M |
| March 31, 2023 | 102.49M |
| December 31, 2022 | 517.07M |
| September 30, 2022 | 2.973M |
| June 30, 2022 | 26.63M |
| March 31, 2022 | 26.59M |
| December 31, 2021 | 1.691M |
| September 30, 2021 | 0.896M |
| June 30, 2021 | 1.148M |
| March 31, 2021 | 0.351M |
| December 31, 2020 | 0.075M |
| September 30, 2020 | 0.162M |
| Date | Value |
|---|---|
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.7886M |
| January 31, 2020 | 0.00 |
| October 31, 2019 | 0.00 |
| July 31, 2019 | 0.00 |
| April 30, 2019 | 0.00 |
| January 31, 2019 | 0.00 |
| October 31, 2018 | 0.00 |
| July 31, 2018 | 0.00 |
| April 30, 2018 | 1.384M |
| January 31, 2018 | 0.00 |
| October 31, 2017 | 0.00 |
| July 31, 2017 | 0.00 |
| April 30, 2017 | 0.00 |
| January 31, 2017 | 0.00 |
| October 31, 2016 | 0.00 |
| July 31, 2016 | 0.00 |
| April 30, 2016 | 0.00 |
| January 31, 2016 | 0.00 |
| October 31, 2015 | 0.00 |
| July 31, 2015 | 0.00 |
| April 30, 2015 | 0.00 |
| January 31, 2015 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| NovelStem International Corp. | 1.620M |
| Brainstorm Cell Therapeutics, Inc. | 0.00 |
| Kezar Life Sciences, Inc. | 0.00 |
| Protara Therapeutics, Inc. | 1.463M |
| Clene, Inc. | 21.53M |